Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial

dc.contributor.authorSarasate, Mikel
dc.contributor.authorGonzález, Nuria
dc.contributor.authorCórdoba Izquierdo, Ana
dc.contributor.authorPrats, Enric
dc.contributor.authorRodríguez González-Moro, Jose Miguel
dc.contributor.authorMartí, Sergi
dc.contributor.authorLujan, Manel
dc.contributor.authorCalle, Myriam
dc.contributor.authorAntón, Antonio
dc.contributor.authorPovedano, Mónica
dc.contributor.authorFarrero, Eva
dc.date.accessioned2023-10-06T17:09:09Z
dc.date.available2023-10-06T17:09:09Z
dc.date.issued2023-07-04
dc.date.updated2023-09-04T12:56:52Z
dc.description.abstractBackground and objective: Forced vital capacity (FVC) less than 50% of predicted is one of the main parameters used for Non-Invasive Ventilation (NIV) initiation in Amyotrophic Lateral Sclerosis (ALS). Recent studies suggest that higher values of FVC could be considered as a threshold. The aim of this study is to evaluate whether early use of NIV improves the prognosis of ALS patients compared with standard initiation. Methods: This is a randomized, parallel, multicenter, open-label, controlled clinical trial, with recruitment at the ALS outpatient multidisciplinary units of six Spanish hospitals. Patients were included when their FVC reached the 75% threshold and were randomized by computer, stratifying by center in an allocation ratio of 1:1 to Early NIV (FVC below 75%) or Standard NIV (FVC below 50%) initiation. The primary outcome was time to death or tracheostomy. Trial registration number ClinicalTrials.gov: NCT01641965. Results: Between May 2012 and June 2014, 42 patients were randomized to two groups, 20 to Early NIV and 22 to Standard NIV initiation. We found differences in survival in favor of the intervention group: an incidence of mortality (2.68 [1.87-5.50] vs. 3.33 [1.34-4.80] person-months) and a median survival (25.2 vs. 19.4 months), although without reaching statistical significance (p = 0.267). Conclusions: This trial did not reach the primary endpoint of survival; nevertheless, it is the first Randomized Controlled Trial (RCT) to demonstrate the benefits of early NIV in slowing the decline of respiratory muscle strength and reducing adverse events. Although not all the results reached statistical significance, all the analyzed data favor early NIV. In addition, this study demonstrates good tolerance and compliance with early NIV without quality of sleep impairment. These data reinforce the early respiratory evaluation of ALS patients and NIV initiation with an FVC of around 75%.
dc.format.extent11 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2214-3599
dc.identifier.pmid37212068
dc.identifier.urihttps://hdl.handle.net/2445/202533
dc.language.isoeng
dc.publisherIOS Press
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3233/JND-221658
dc.relation.ispartofJournal of Neuromuscular Diseases, 2023, vol. 10, num. 4, p. 627-637
dc.relation.urihttps://doi.org/10.3233/JND-221658
dc.rightscc by-nc (c) Sarasate, Mikel et al., 2023
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationEsclerosi lateral amiotròfica
dc.subject.classificationRespiració artificial
dc.subject.otherAmyotrophic lateral sclerosis
dc.subject.otherArtificial respiration
dc.titleImpact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
jnd-10-jnd221658.pdf
Mida:
421.86 KB
Format:
Adobe Portable Document Format

Paquet de llicències

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
license.txt
Mida:
1.71 KB
Format:
Item-specific license agreed upon to submission
Descripció: